March 31, 2021 Radiotherapeutics remain in the deal-making frame A radionuclide deal between Lantheus and Noria mirrors that done by Novartis and Sofie, among others.
March 18, 2021 Takeda spreads it bets in Huntington’s The Japanese group pays $120m for Anima’s preclinical small-molecule approach.
January 12, 2021 Novartis turns to Beigene for a PD-1 blocker The pharma giant resorts to deal-making for a much-needed late-stage IO asset, leaving its own PD-1 agent out in the cold.